Teva Pharmaceutical Industries (TEVA) Long-Term Debt Repayments (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Long-Term Debt Repayments came in at $23.0 million in Q1 2026, down 94.82% on a QoQ basis from $444.0 million in Q3 2025.
Teva Pharmaceutical Industries (TEVA) Long-Term Debt Repayments (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Long-Term Debt Repayments data on file, last reported at $23.0 million in Q1 2026.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to $23.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 billion (up 68.62% YoY) and the FY2025 annual result came in at $4.1 billion, up 150.58% from the prior year.
- Long-Term Debt Repayments declined to $23.0 million in Q1 2026, from $444.0 million in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $3.2 billion in Q1 2023 to a low of $23.0 million in Q1 2026.
- A 5-year average of $992.9 million and a median of $696.5 million in 2022 frame the typical range for Long-Term Debt Repayments.
- Annual changes were most pronounced in 2022 — Long-Term Debt Repayments tumbled 86.32% — and 2023, when it surged 173.97%.
- Tracing TEVA's Long-Term Debt Repayments over 5 years: stood at $708.0 million in 2022, then soared by 41.24% to $1.0 billion in 2023, then plunged by 31.5% to $685.0 million in 2024, then sank by 35.18% to $444.0 million in 2025, then sank by 94.82% to $23.0 million in 2026.
- The last three Long-Term Debt Repayments figures came in at $23.0 million (Q1 2026), $444.0 million (Q3 2025), and $2.3 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -156,847.56 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.00 Mn |
| Mar 31, 2026 | 23.00 Mn |
| Sep 30, 2025 | 444.00 Mn |
| Sep 30, 2025 | 444.00 Mn |
| Jun 30, 2025 | 2.30 Bn |
| Jun 30, 2025 | 2.30 Bn |
| Dec 31, 2024 | 685.00 Mn |
| Dec 31, 2024 | 685.00 Mn |
| Jun 30, 2024 | 956.00 Mn |
| Jun 30, 2024 | 956.00 Mn |
| Sep 30, 2023 | 1.00 Bn |
| Sep 30, 2023 | 1.00 Bn |
| Mar 31, 2023 | 3.15 Bn |
| Mar 31, 2023 | 3.15 Bn |
| Dec 31, 2022 | 708.00 Mn |
| Dec 31, 2022 | 708.00 Mn |
| Sep 30, 2022 | 365.00 Mn |
| Sep 30, 2022 | 365.00 Mn |
| Jun 30, 2022 | 296.00 Mn |
| Jun 30, 2022 | 296.00 Mn |